Picture of BioNTech SE logo

BNTX BioNTech SE Cashflow Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousLarge CapHigh Flyer

Annual cashflow statement for BioNTech SE, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.

2021
December 31st
2022
December 31st
2023
December 31st
2024
December 31st
2025
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:20-F20-F20-F20-F20-F
Standards:
IFRS
IFRS
IFRS
IFRS
IFRS
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line15,04612,9541,186-678-1,051
Depreciation
Non-Cash Items-32.6248-577-551282
Unusual Items
Other Non-Cash Items
Changes in Working Capital-14,1992524,5791,138842
Change in Accounts Receivable
Change in Inventories
Change in Accounts Payable
Other Operating Cash Flow
Cash from Operating Activities89013,5775,371208456
Capital Expenditures-154-363-706-452-749
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items-412328-6,249-1,629-1,720
Acquisition of Business
Sale of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities-566-35.3-6,955-2,081-2,469
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities94.2-1,419-779-45.9-52.9
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash48312,182-2,211-1,902-2,087